A single infusion costing approximately $2 million, the most expensive drug ever covered by Japan's public health insurance, has just been approved. For children suffering from a devastating disease that gradually destroys every muscle in their body, this new gene therapy represents both extraordinary hope and a profound test of how far a nation's healthcare system can stretch to save its youngest citizens.

The Most Expensive Drug in Japan's History

On February 20, 2026, a gene therapy called Elevidys (generic name: delandistrogene moxeparvovec) became covered under Japan's public health insurance system. It treats Duchenne muscular dystrophy (DMD), a rare and devastating genetic disease. The official price tag: 304,972,042 yen, approximately $2 million per patient, making it the most expensive insured drug in Japan's history.

The previous record holder was Zolgensma, a treatment for spinal muscular atrophy priced at 167 million yen (about $1.1 million). Elevidys is roughly 1.8 times more expensive, marking a new milestone in Japan's healthcare landscape.

For comparison, Elevidys is priced at about $3.84 million (roughly ¥572 million) in the United States, meaning Japan's price is actually lower than its American counterpart.

What Is Duchenne Muscular Dystrophy?

Duchenne muscular dystrophy (DMD) is a progressive genetic disorder caused by mutations in the gene responsible for producing dystrophin, a protein essential for maintaining healthy muscle cells. It primarily affects boys, occurring in approximately 1 in every 5,000 male births worldwide.

Early symptoms often appear as difficulty running or frequent falls in toddlers. As the disease progresses, most patients lose the ability to walk by their early teens. Eventually, the muscles controlling breathing and heart function also deteriorate, requiring ventilators and cardiac support. Many patients do not survive beyond their 20s or 30s. Until recently, there was no fundamental treatment, only steroid therapy to slow the disease's progression.

How Does Elevidys Work?

Elevidys uses a viral vector (essentially a harmless virus repurposed as a delivery vehicle) to introduce a gene encoding "micro-dystrophin" into the patient's body. This shortened version of the dystrophin protein is designed to protect muscle cells from the destruction caused by DMD.

The treatment requires only a single intravenous infusion, with no repeat doses needed. Because the full dystrophin gene is too large to fit inside the viral vector, scientists engineered a compact version that retains the protein's most critical protective functions.

However, eligibility is strictly limited. Only patients aged 3 to 7 (under 8) who can still walk and who test negative for specific antibodies (anti-AAVrh74 antibodies) qualify for treatment.

The Road to Approval and Safety Concerns

Elevidys was originally developed by Sarepta Therapeutics, a U.S.-based biotech company. In Japan, it is supplied by Chugai Pharmaceutical, a subsidiary of Swiss pharma giant Roche.

The U.S. FDA first granted accelerated approval in June 2023 for ambulatory children aged 4–5, later expanding it to patients aged 4 and older in 2024. Japan's Ministry of Health granted "conditional and time-limited approval" (valid for three years) in May 2025. This regulatory pathway allows drugs to reach patients when effectiveness has been "estimated" rather than fully confirmed, with ongoing data collection required.

Safety concerns have also emerged. In June 2025, two patients overseas who received the drug while non-ambulatory died from acute liver failure. Following these reports, Chugai temporarily suspended domestic shipments and revised the drug's labeling with additional safety measures; the insurance review, which had been paused, resumed only after these steps. Chugai has stated it will continue monitoring safety data and implement additional measures as needed.

How Much Do Patients Actually Pay?

Despite the staggering price, Japan's layered healthcare safety net ensures that patients bear very little of the cost directly. Here's how:

Universal Health Insurance (国民皆保険 / Kokumin Kai Hoken): Japan's system requires all residents to have health insurance, with patients typically paying 20–30% of medical costs at the point of service. For a $2 million drug, that would still amount to hundreds of thousands of dollars, but that's where additional protections kick in.

High-Cost Medical Expense System (高額療養費制度 / Kōgaku Ryōyōhi Seido): This system caps monthly out-of-pocket expenses based on the patient's household income. For a typical middle-income family, the monthly ceiling is roughly $580–$600 (about 87,000–90,000 yen). Anything above this cap is covered by the insurance system.

Designated Intractable Disease Subsidies: DMD is recognized as a designated intractable disease ("nanbyo") under national policy, qualifying patients for additional government subsidies that further reduce costs.

Local Government Child Medical Programs: Many Japanese municipalities offer free medical care for children, sometimes up to age 15 or even 18, further reducing the financial burden.

Through these combined mechanisms, the actual out-of-pocket cost for a family can be reduced to near zero.

The Sustainability Challenge

While Elevidys represents hope for DMD patients, it raises serious questions about the long-term sustainability of Japan's healthcare system.

The Ministry of Health estimates that only about 37 patients per year will receive the drug at peak demand, with a market size of approximately 11.3 billion yen ($74 million). Officials have described the fiscal impact as "limited." But Elevidys is not an isolated case. Japan has been approving a growing number of ultra-expensive drugs in recent years, including CAR-T cell therapies like Kymriah (about $220,000) and new Alzheimer's treatments like Leqembi, each adding cumulative pressure to the insurance system.

This comes at a time when Japan is already debating whether to raise the caps on the High-Cost Medical Expense System. A proposed increase was shelved in 2025 after public backlash, but discussions continue around income-based tiered increases. Patient advocacy groups worry that raising these caps could discourage people from seeking necessary care.

The Age Limit Dilemma

One of the most heart-wrenching aspects of Elevidys is its narrow eligibility window. With the drug limited to children aged 3 to 7, families face a race against time. Takeda Tamotsu, chairman of the Japan Muscular Dystrophy Association, has expressed concern that some children may age out of eligibility before hospitals in their area are ready to administer the treatment.

For children with a progressive disease, every day matters. As one advocate put it: "What a patient can do today, there is no guarantee they can still do tomorrow." The urgency to establish infusion-ready facilities across the country is palpable.

Beyond the Price Tag

The $2 million figure is eye-catching, but context matters. This is a one-time treatment with the potential for lifelong benefit. Without it, the cumulative cost of wheelchairs, ventilators, round-the-clock care, rehabilitation, and repeated hospitalizations over a patient's lifetime could rival or exceed the drug's price.

The real question isn't whether expensive drugs are worth the money, it's how societies can build healthcare systems that ensure no one is left behind as medical science advances at breathtaking speed. Japan's universal healthcare model, one of the most comprehensive in the world, is being put to the test by the gene therapy era.

In Japan, the arrival of ultra-expensive gene therapies is sparking a national conversation about balancing the value of human life with fiscal sustainability. How does your country handle treatments that cost millions of dollars? Is there a public insurance system that covers them, or are patients left to navigate costs on their own? We'd love to hear how things work where you live.

References